SeQuent Please OTW 018

B. Braun Melsungen AG
+49 (0) 30 568207 300


• Low profile (4/5 F)
• Can be used above and below the knee
• Diameter availability ranges from 2 to 6 mm with balloon lengths up to 120 mm
• Supplements B. Braun’s existing 0.014- and 0.035-inch DCB portfolio

The recently launched low-profile SeQuent Please OTW 018 drug-coated balloon (DCB) is the key for treating infrapopliteal and femoropopliteal lesions. It enables the operator to use small sheath sizes of 4/5 F combined with a 0.018-inch guidewire. SeQuent Please OTW 018 is a paclitaxel-resveratrol–coated balloon catheter.

SeQuent Please OTW was investigated in the CONSEQUENT randomized controlled trial.1 Patients (n = 153) with challenging femoropopliteal lesions (23.5% with TASC [TransAtlantic Inter-Society Consensus] C and D lesions; mean lesion length, 14.5 cm) were randomized 1:1 to DCB versus plain old balloon angioplasty. At 24 months, primary patency was significantly higher in the DCB group (72.3% vs 48.4%; P = .006) with no further target lesion revascularization after 14 months.

SeQuent Please OTW 018 is available in diameters ranging from 2 to 6 mm and balloon lengths up to 120 mm.

1. Albrecht T, Waliszewski M, Roca C, et al. Two-year clinical outcomes of the CONSEQUENT trial: can femoropopliteal lesions be treated with sustainable clinical results that are economically sound? Cardiovasc Intervent Radiol. 2018;41:1008-1014.

Magic Glue

+33 1 39 89 46 41


• New cyanoacrylate glue
• Delayed polymerization for better control1
• Reduced adhesive strength to the microcatheter for longer injection1

Balt is proud to announce that Magic Glue has received CE Mark approval. Magic Glue is a next-generation cyanoacrylate liquid embolic agent, indicated for use in the embolization of arteriovenous malformations. Magic Glue is a class III implantable medical device described as an arterial and venous embolization implant due to its hemostatic action, and it is applicable in the fields of neuroradiology and interventional radiology. The device is applied in solution with a contrast liquid.

This cyanoacrylate glue offers interesting features, including delayed polymerization of the monomers for better control and reduced adhesive strength to the microcatheter for longer injection.1 With these characteristics, Magic Glue will expand cyanoacrylate indication in the neurovascular and peripheral fields, noted company President Nicolas Plowiecki.

1. Izaaryene J, Saeed Kilani M, Rolland PH, et al. Preclinical study on an animal model of a new non-adhesive cyanoacrylate (Purefill®) for arterial embolization. Diagn Interv Imaging. 2016;97:1109-1116.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.